Market Overview:
Global Autism Disorder & Treatment Market is expected to grow at a CAGR of 4.37% during the forecast period 2017–2023. Growing burden of autism in western countries has majorly contributed to the growth of the market and is likely to increase due to growing number of cases of autism around the globe in the coming years which will also boost the market growth during the forecast period.
Avail Exclusive Sample Copy of Autism Disorder and Treatment Market `spread across 108 Premium Pages, 10+ and Supported with Full TOC, is Available @ https://www.marketresearchfuture.com/sample_request/1605
Environmental and genetic factors are major factors which have majorly increased the prevalence of autism disorder, and it is expected to increase in the coming decade due to various factors such as poor nutritional conditions of children and adolescents, increasing environmental toxins and increasing prenatal and perinatal maternal stress. According to a recent epidemiological study, it has been observed that around 87% of the ASD cases are from Europe, Japan, and North America, while only 10% of the world’s children live in these countries. Moreover, the Centers for Disease Control’s (CDC) Autism and Developmental Disabilities Monitoring (ADDM) society stated that approximately 1 in 68 children in the United States was identified with an Autism Spectrum Disorder (ASD) in 2016.
Drivers and Restraints:
The rise in cases of autism combined with environmental and genetic factors are factors expected to spur market demand during the forecast period. According to a 2016 report by the Centers for Disease Control and Prevention (CDC) autism division, 1 in 68 children had a probability of being diagnosed with autism in the United States. Initiatives of various nations to create awareness regarding autism and approval of off-label drugs by the U.S. Food and Drug Administration (FDA) can create opportunities for growth. A weak drug pipeline by manufacturers coupled with stringent regulations can deter market prospects.
Breakthroughs:
According to a study in 2017 by researchers of the University of California at Davis and Massachusetts Institute of Technology (MIT), R-Baclofen, a drug possessed the capacity to reverse cognitive defects of the 16p11.2 disorder in mice. The drug can enhance the performance of cognitive tasks and male-female social interactions. Furthermore, successful trials of the drug can be used in treating ASD and autism.
Private equity players are investing in autism treatment due to high potential returns. Changes in reimbursement packages and demand for treatment services are expected to lead to heavy inflow of capital in the healthcare sector. In 2017, FFL Partners, a U.S. firm completed its acquisition of Autism Learning Partners, a provider of applied behavioral analysis for autistic patients.
Ask any Queries to Experts about Niche Segments, Requires Regional Data and Top Players @ https://www.marketresearchfuture.com/enquiry/1605
Competition Outlook:
Key market players include Eli Lilly and Company, Allergan plc, Teva Pharmaceutical Industries Ltd., Novartis International AG, and Bristol-Myers Squibb. These players are focusing on extensive research and development to produce effective medicines to counter autism. Approvals from regulatory agencies and introduction of new drugs can play a major role in market growth.
Segmentation:
The autism and disorder treatment market is segmented by type, treatment type, and drugs. By type, the market caters to Pervasive Developmental Disorder, Asperger Syndrome, and others. The pervasive developmental disorder segment is estimated to exhibit a 4.79% CAGR till 2023.
Different types of treatment for autism covered in the market include hyperbaric oxygen therapy, oxytocin therapy, chelation therapy, applied behavioral analysis (ABA), and others. The ABA segment is anticipated to grow at a 4.82% CAGR during the forecast period.
Major drugs comprise anti-psychotics, anti-convulsants, selective serotonin reuptake inhibitors (SSRIs), and stimulants. The anti-psychotics segment is sub-divided into Risperidone and Abilify (aripiprazole). The anti-psychotics segment is touted to expand at a 3.95% CAGR over the forecast period.
Major TOC of Autism Disorder and Treatment Market Research Report – Forecast to 2023:
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
3 RESEARCH METHODOLOGY
4 MARKET DYNAMICS
5 MARKET FACTOR ANALYSIS
6 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TYPE
7 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY TREATMENT TYPE
8 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY DRUGS
9 GLOBAL AUTISM DISORDER & TREATMENT MARKET, BY REGION
10 COMPETITIVE LANDSCAPE
11 COMPANY PROFILES
12 CONCLUSION
13 APPENDIX
Avail Dazzling Discount @ https://www.marketresearchfuture.com/check-discount/1605
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605